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Nephrotic syndrome is a chronic renal disease that can lead to end stage renal disease. There are
different histological types with global variations in frequency. Literatures reviewed showed that the African
variant is less likely to be minimal change variant. No clear treatment protocol for it has been most beneficial.
This paper aims to evaluate the outcome of a treatment protocol using cyclophosphamide and
prednisolone concurrently.
A low dose and short duration concurrent use of cyclophosphamide and prednisolone was used for
treating children with nephrotic syndrome who had not developed derangements of their renal function. The
case files of those that were treated and followed up over a 10 year period or until they were above 18years of
age were analysed for their clinical parameters.
Five cases were treated and all have been in clinical remission for more than 4 years as at the time of
the review, though 2 of them relapsed twice initially. They were all aged above 6 years and had microscopic
hematuria. The 3 cases whose ESRs were done had high levels. Two cases that presented 1 yr after the onset of
their symptoms resolved without relapse while 2 out of the remaining 3 in whom this interval was less than 6
months relapsed.
This treatment protocol appears beneficial to childhood nephrotics in this environment and
should be used.
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INTRODUCTION
Nephrotic syndrome is a clinical condition of
oedema and proteinuria (>1gm/M /24hrs or
40mg/M /hr) in which the renal histology (light
microscopy) demonstrates fatty degeneration of the
tubules associated with normal appearing glomeruli.
The oedema in this chronic renal disease follows the
hypoproteinaemia (serum albumin level of <2.5g/dl)
that results from the massive proteinuria. The
different renal histological findings include the
minimal change nephrotic syndrome (MCNS)
which constitutes about 84.5% of cases; focal
segmental glomerulosclerosis, (FSGS) 9.5%;
membranoproliferative glomerulonephritis
( M P G N ) , 2 . 5 % a n d m e m b r a n o u s
glomerulonephritis (MGN), the remaining
percentage. African children with nephrotic
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In a study of nephrotic syndrome in children aged 3
16 years in Ilorin, Nigeria, out of the 8 biopsies that
were done, focal mesangial proliferative
glomerulonephritis was seen in 63% while minimal
change, membranoproliferative and mesangial
proliferative glomerulonephritis were equally
distributed amongst the remaining.
The diagnosis which is both clinical and laboratory is
based on the presence of oedema, hypoproteinemia
and massive proteinuria. Uncomplicated cases have
normal serum urea, electrolytes and creatine levels,
though some may have hematuria. Though the
hypoproteinemia in this condition is not the only
cause of the oedema that makes most of them to
present, however the loss of oncotic pressure
subsequent on the hypoproteinemia initiates all the
bodily responses 24 culminating in the oedema.
Without intervention, persistent proteinuria of the
magnitude in nephrotic syndrome is expected to
ultimately lead to oedema.
Though a chronic disease, spontaneous remission,
especially with the minimal change histological type,
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is speculated to often occur, whilst a few will
progress to end-stage renal disease.
Drug treatment has offered the best chance of
reversing the renal process and resolving the
biochemical derangements and clinical features.
Steroids were initially found to be very useful, and
although more than 80% of patients with MCNS
responded to the steroids steroid responders,
unfortunately, 50-60% of these steroid responders
developed frequent relapses or became steroid
dependent. The prolonged use of steroids in the
frequent relapsers and steroid dependents also made
them to suffer from the adverse effects of steroid
therapy. The other histological types on the other
hand were poorly responsive to steroids. These
setbacks led to the discovery of the cytotoxics, and
the alkylating agents cyclophosphamide and
chloroambucil were found beneficial when
steroids failed. Due to the initial favourable
response of the commoner MCNS to steroids, the
mainstay of treatment or the first line drug for the
treatment of nephrotic syndrome became the
steroids. The need to improve treatment outcome
resulted in the use of the effective drugs singly
or as a combination; sequentially and
concurrently. There appears to be a consensus that
the combination therapy gave better results than
single drug therapy. Combination treatment have
been found useful in other chronic ailments e.g.
tuberculosis, HIV/AIDS and hypertension and
nephrotic syndrome, a chronic ailment may not be
much different.
Many factors however affect the outcome of drug
treatment in nephrotic syndrome and include; the
histological type, first presentation or relapse, age
of the child at the onset, duration of
treatment, type of drug, type of response to
steroid therapy, dose of the drug, the renal
function status and the patient's race.
Long remission periods have been associated with
the use of cyclophosphamide either sequential to or
in combination with steroids. A comparative
analysis studying the effect of a low dose
(2.5mg/kg/day) and a high dose (5mg/kg/day)
cyclophosphamide over a period showed that low
dose used long enough was capable of giving good
results while at the same time avoiding the toxic or
side effects of a high dose. A study, using a dose of
3mg/kg/day for 8 weeks, showed beneficial results
and concluded that a lower dose may work and that
for children, shorter durations may even be
effective.
McCrory et al had commented that there is no
agreement regarding the most desirable program of
therapy for children with nephrotic syndrome. They





















effective therapy to control or prevent relapses. Tune
et al shared the same view when they suggested that
the present conservative approach to the management
o f s t e r o i d r e s i s t a n t f o c a l s e g m e n t a l
glomerulosclerosis should be changed since this
condition is more likely to progress to end-stage renal
disease.
There is therefore the need to work out treatment
modality or modalities that will be most beneficial to
these patients especially for those in this environment
that are not likely to be the MCNS type.
This study therefore tried to look at the outcome of
children presenting with nephritic syndrome who
were treated with a low dose short course of
cyclophosphamide and prednisolone.
All the children that presented with oedema,
hypoproteinemia and massive proteinuria but
without deranged serum urea, electrolyte and
creatine values seen over a ten year period (Nov 1994
Oct 2004) in a children's specialist hospital at
Onitsha, Southeast Nigeria were enrolled after
explanation.
Information to be obtained included their ages, sexes,
blood pressures, complete blood count and
erythrocyte sedimentation rates, serum urea,
electrolytes and creatine, serum proteins, 24hr
urinary protein, urine stripe test for protein and rbcs
using Combur . Abdominal ultrasound was done
when abnormal masses were palpated par abdomen.
Patients were followed up and their blood pressures,
serum proteins and urinalysis were monitored.
A concurrent use of low dose and short duration
protocol using cyclophosphamide and prednisolone
was used in treating the children. It consisited of:
Cyclophosphamide in a dose of 2 2.5
mg/kg/day to the approximate total dose
obtainable from the available tablet strength of
100mg/tablet. This was given once daily for a
total of 8 weeks. The dosage was adjusted as the
patient's weight changed with loss of oedema.
Prednisolone was given in a dose of 1.5
mg/kg/day to achieve an approximate total
daily dose divisible by 5 since the tablets are in
5mgs strength. It was given in two divided
doses and for a total of 12 weeks, with dose
adjustment according to changes in the patient's
body weight. After 10 weeks, the dose was
tapered off at the rate of 0.5 mg/wk.
Adjunctive therapy of furosemide in a dose of 2
4 mg/kg/day in two divided doses was given to
those with discomforting oedema or anarsaca.
Other clinical problems e.g. infections that were
present were treated appropriately.
Relapses during follow up were documented and
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however had deranged renal functions and were not
treated here but were referred while another two
objected to the treatment. The 5 remaining case files
were then evaluated.
Table 1 shows the epidemiological features of the
patients, any other problems detected, additional
treatment given and duration of remission.
Table 2 shows the laboratory results before institution
of treatment.
No renal biopsies were done on them.
practice and since a pattern seemed to have been
observed with these 5 cases, it was thought
worthwhile to communicate a preliminary report on
the evolving pattern.
Finally, no clear different protocol was used for the
relapsed cases. It is pertinent to also mention that
none relapsed within less than 6 months period.
The clinical feature, oedema, which the patients
related to was used as the determinant of their
clinical state i.e. remitted or relapsed.
They were followed up to the time of the report or, up
to the age 18 years if they attain that age before the
time of the report.
Nine case files were identified as cases of nephrotic
syndrome seen over the 10 year period. Two
The 1st three attained 18 years and stopped coming
for consultation.
yrs - years, mths - months,
wks - week, pres. - presentation
Table 2:
Pt id = patient identity, Alb = Albumin, Glo =
Globulin
Unfortunately, time, distance and costs constraints
made the necessary blood and urinary biochemical
monitoring difficult.
Secondly, 5 cases are inadequate for statistical
conclusions but nephrotic syndrome is not a very
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In this review, there were 4 males and one female
which is in keeping with involvement of more males
than females in nephrotic syndrome.
Though two cases relapsed, all of them ultimately
went into clinical remission, with the least having
been in remission for 48 months now. On the other
hand, when only steroids were used, the percentage
of steroid responders reduced with time. Though all
the cases had hematuria, which could also be found
in MCNS, the presence of a high ESR in those
monitored would suggest that these nephrotics were
secondary in origin. That would have meant poor
response to treatment as found by some workers. In
this review however, two of the initial 3 responders
had high ESRs.
Considering the impact of age, they were all above 6
years of age and this may have improved their
chances of going into remission since it is known
that if the age is less than 6 years, they tended to
relapse into adulthood.
Additionally, some other workers have shown that
the shorter the time of onset to treatment, the better
the response to treatment. This review has findings
at variance with this view because the two cases that
lasted for more than 12 months before the onset of
treatment resolved with the first course while 2 out
of the 3 cases that were less than 6 months relapsed 2
times over.
This review also showed that the second relapse
took a shorter time than the first to manifest which is
the finding in other studies. The subsequent relapse
amongst the relapsed cases tends to reinforce the
view that a history of relapse increases the frequency
of subsequent relapses.
This low dose short duration concurrent use of
cyclophosphamide and prednisolone in the
treatment of nephrotics seems to offer good results
that may be comparative to others. Generally, whilst
low dose cyclophosphamide and short duration
prednisolone were associated with relapses, this
concurrent use of both drugs in this manner seemed
to have had a synergistic action of both drugs on the
disease process. Other studies seem to support this
view.
From the foregone therefore, it is probable that the
concurrent use of cyclophosphamide and
prednisolone in the treatment of nephrotics in this
environment maybe a type of the non-conservative
management of secondary nephrotics that was
advocated for by Tune et al.
These findings could result in the childhood
nephrotics in our environment enjoying fewer
hospital consultations consequent upon fewer
relapses, better health without the otherwise
laborious medication schedules and the consequent
positive impact of these on their socio-economic
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ERRATUM
In our previous publication titled Neurological Complications of
Chronic Myeloid Leukaemia:Any Cure? Vol 11(3): 246-249.
The authors’ names appeared as J D Emmanuel and M A
Dorusinmi.
The correct names are D E Joseph and MADurosinmi.
The errors are regretted.
